ATE187071T1 - Stabilisiertes prostaglandin e1 - Google Patents

Stabilisiertes prostaglandin e1

Info

Publication number: ATE187071T1
Authority: AT; Austria
Prior art keywords: formulation; lactose; pct; pge; tertiary butyl
Prior art date: 1993-10-27

Application number

AT94927958T

Other languages

English (en)

Inventor

Dirk L Teagarden

William J Petre

Paul M Gold

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-27

Filing date

1994-09-06

Publication date

1999-12-15

1994-09-06 Application filed by Upjohn Co filed Critical Upjohn Co

1999-12-15 Application granted granted Critical

1999-12-15 Publication of ATE187071T1 publication Critical patent/ATE187071T1/de

Links

GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title abstract 4
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title abstract 2
229960000711 alprostadil Drugs 0.000 title abstract 2
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title abstract 2
238000009472 formulation Methods 0.000 abstract 5
239000000203 mixture Substances 0.000 abstract 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 4
239000008101 lactose Substances 0.000 abstract 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 abstract 3
230000008014 freezing Effects 0.000 abstract 2
238000007710 freezing Methods 0.000 abstract 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
239000007853 buffer solution Substances 0.000 abstract 1
238000001035 drying Methods 0.000 abstract 1
239000012931 lyophilized formulation Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000007524 organic acids Chemical class 0.000 abstract 1
150000003180 prostaglandins Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1
238000010792 warming Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT94927958T 1993-10-27 1994-09-06 Stabilisiertes prostaglandin e1 ATE187071T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US14369593A	1993-10-27	1993-10-27

Publications (1)

Publication Number	Publication Date
ATE187071T1 true ATE187071T1 (de)	1999-12-15

Family

ID=22505188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94927958T ATE187071T1 (de)	1993-10-27	1994-09-06	Stabilisiertes prostaglandin e1

Country Status (16)

Country	Link
US (2)	US5741523A (de)
EP (1)	EP0725642B1 (de)
JP (1)	JP3999263B2 (de)
KR (1)	KR100335549B1 (de)
CN (1)	CN1060042C (de)
AT (1)	ATE187071T1 (de)
AU (1)	AU688792B2 (de)
DE (1)	DE69421936T2 (de)
DK (1)	DK0725642T3 (de)
ES (1)	ES2142409T3 (de)
FI (1)	FI116270B (de)
GR (1)	GR3032817T3 (de)
NO (1)	NO309126B1 (de)
NZ (1)	NZ273752A (de)
PT (1)	PT725642E (de)
WO (1)	WO1995011683A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
KR100195348B1 (ko) *	1996-10-31	1999-06-15	장용택	안정한 프로스타글란딘 e1-함유 주사제 조성물
US6103765A (en)	1997-07-09	2000-08-15	Androsolutions, Inc.	Methods for treating male erectile dysfunction
WO1999002147A1 (en)	1997-07-09	1999-01-21	Androsolutions, Inc.	Improved methods and compositions for treating male erectile dysfunction
JP2002505282A (ja) *	1998-03-03	2002-02-19	塩野義製薬株式会社	ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
US6486207B2 (en)	1998-12-10	2002-11-26	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en)	1998-12-10	2004-11-30	Nexmed (Holdings) , Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US6264981B1 (en) †	1999-10-27	2001-07-24	Anesta Corporation	Oral transmucosal drug dosage using solid solution
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
EP1677738A2 (de) *	2003-10-31	2006-07-12	Point Biomedical Corporation	Rekonstituierbare mikrokugel-zusammensetzungen als ultraschall-kontrastmittel
CN101933923A (zh) *	2004-11-05	2011-01-05	赛福伦公司	癌症治疗
US7464012B2 (en) *	2004-12-10	2008-12-09	L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude	Simplified process simulator
US7582312B2 (en) *	2004-11-15	2009-09-01	Discovery Laboratories, Inc.	Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8436190B2 (en)	2005-01-14	2013-05-07	Cephalon, Inc.	Bendamustine pharmaceutical compositions
JPWO2006075690A1 (ja) *	2005-01-14	2008-06-12	小野薬品工業株式会社	安定な医薬組成物
US9005183B2 (en) *	2007-05-16	2015-04-14	Health Knight, Llc	System and method for treating erectile dysfunction
US20100222785A1 (en) *	2007-08-03	2010-09-02	Vanderbilt University	Anchor driver
AR072777A1 (es) *	2008-03-26	2010-09-22	Cephalon Inc	Formas solidas de clorhidrato de bendamustina
WO2010036702A1 (en) *	2008-09-25	2010-04-01	Cephalon, Inc.	Liquid formulations of bendamustine
UA109109C2 (uk) *	2009-01-15	2015-07-27	Сефалон, Інк.	Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
ES2609106T5 (es)	2010-01-28	2020-11-10	Eagle Pharmaceuticals Inc	Formulaciones de bendamustina
US10342769B2 (en)	2014-11-14	2019-07-09	Navinta Iii Inc	Carmustine pharmaceutical composition
AT518009A1 (de) *	2015-07-27	2017-06-15	Gebro Holding Gmbh	Konzentrat enthaltend Alprostadil
CN109394704B (zh) *	2018-11-27	2021-09-17	西安力邦肇新生物科技有限公司	一种前列腺素e1甲酯注射用冻干制剂及制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3927197A (en) *	1974-04-19	1975-12-16	Pfizer	Tertiary alcohol stabilized E-series prostaglandins
US3952004A (en) *	1974-06-18	1976-04-20	Pfizer Inc.	Stabilized E-series prostaglandins
US4113882A (en) *	1974-10-21	1978-09-12	Yamanouchi Pharmaceutical Co., Ltd.	Stabilized oral prostaglandin formulation and the process for the preparation thereof
WO1988009170A1 (en) *	1987-05-22	1988-12-01	The Liposome Company, Inc.	Prostaglandin-lipid formulations

1994
- 1994-09-06 AT AT94927958T patent/ATE187071T1/de not_active IP Right Cessation
- 1994-09-06 PT PT94927958T patent/PT725642E/pt unknown
- 1994-09-06 CN CN94193888A patent/CN1060042C/zh not_active Expired - Fee Related
- 1994-09-06 AU AU77167/94A patent/AU688792B2/en not_active Ceased
- 1994-09-06 ES ES94927958T patent/ES2142409T3/es not_active Expired - Lifetime
- 1994-09-06 JP JP51260495A patent/JP3999263B2/ja not_active Expired - Lifetime
- 1994-09-06 EP EP94927958A patent/EP0725642B1/de not_active Expired - Lifetime
- 1994-09-06 DE DE69421936T patent/DE69421936T2/de not_active Expired - Lifetime
- 1994-09-06 DK DK94927958T patent/DK0725642T3/da active
- 1994-09-06 KR KR1019960702158A patent/KR100335549B1/ko not_active Expired - Fee Related
- 1994-09-06 US US08/619,690 patent/US5741523A/en not_active Expired - Lifetime
- 1994-09-06 NZ NZ273752A patent/NZ273752A/en not_active IP Right Cessation
- 1994-09-06 WO PCT/US1994/009648 patent/WO1995011683A1/en not_active Ceased
1996
- 1996-04-26 FI FI961797A patent/FI116270B/fi active IP Right Grant
- 1996-04-29 NO NO961718A patent/NO309126B1/no not_active IP Right Cessation
- 1996-12-30 US US08/777,132 patent/US5770230A/en not_active Expired - Lifetime
2000
- 2000-02-29 GR GR20000400524T patent/GR3032817T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1995011683A1 (en)	1995-05-04
DE69421936D1 (de)	2000-01-05
AU7716794A (en)	1995-05-22
US5770230A (en)	1998-06-23
DK0725642T3 (da)	2000-05-29
FI116270B (fi)	2005-10-31
KR100335549B1 (ko)	2002-11-29
US5741523A (en)	1998-04-21
JPH09504529A (ja)	1997-05-06
ES2142409T3 (es)	2000-04-16
NZ273752A (en)	1998-03-25
AU688792B2 (en)	1998-03-19
CN1060042C (zh)	2001-01-03
CN1133561A (zh)	1996-10-16
DE69421936T2 (de)	2000-06-29
FI961797L (fi)	1996-04-26
KR960705572A (ko)	1996-11-08
PT725642E (pt)	2000-05-31
JP3999263B2 (ja)	2007-10-31
EP0725642A1 (de)	1996-08-14
NO309126B1 (no)	2000-12-18
NO961718D0 (no)	1996-04-29
FI961797A0 (fi)	1996-04-26
EP0725642B1 (de)	1999-12-01
GR3032817T3 (en)	2000-06-30
NO961718L (no)	1996-04-29

Legal Events

Date	Code	Title	Description
2000-07-15	UEP	Publication of translation of european patent specification
2010-06-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69421936D1 (de)	2000-01-05	Stabilisiertes prostaglandin e1
White et al.	1958	A lipolytic action of epinephrine and norepinephrine on rat adipose tissue in vitro.
BR9707270A (pt)	1999-12-28	Processo para o tratamento de tabaco
DE69823361D1 (de)	2004-05-27	Herstellung von kollagen
SE8702907D0 (sv)	1987-07-17	Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
OIKAWA et al.	1957	The role of calcium in Taka-amylase A
CA2226575A1 (en)	1997-02-13	Stabile isotonic lyophilized protein formulation
RU95105587A (ru)	1996-10-27	Оптически чистые соединения пиридинилметил сульфинил-1н-бензимидазола, их соли, способы получения, фармкомпозиция, способ лечения
EE03047B1 (et)	1997-10-15	Kristalliline veevaba laktitool, selle valmistamise meetod ja kasutamine
KR870006901A (ko)	1987-08-13	인터로이킨-2 조성물의 제조방법
KR890006644A (ko)	1989-06-15	결정성 β-락탐 수화물
MY101132A (en)	1991-07-31	An optically pure pipecoloxylidide hydrochloride and a process for its preparation
US5849473A (en)	1998-12-15	Method of lyophilization of mammalian sperm cells
ATE151643T1 (de)	1997-05-15	Lanolinderivate als penetrationsfördernde substanzen
ZENSER et al.	1974	Effects of prostaglandins on hepatic adenylate cyclase activity and cyclic adenosine 3', 5',-monophosphate content
NO951547D0 (no)	1995-04-24	Fremgangsmåte for fremstilling av krystaller av veksthormon og krystaller fremstilt ved fremgangsmåten
Jennings et al.	1987	Effect of E. coli endotoxin on temperature, oxygen consumption and brown adipose tissue thermogenesis in rats and mice
KR900000544B1 (ko)	1990-01-31	저장성 카모밀레 추출물의 제조방법
PT94078A (pt)	1991-01-08	Processo para a preparacao de derivados de acido butenoico e de composicoes farmaceuticas que os contem
KR840002657A (ko)	1984-07-16	인터페론 조성물의 제조방법
JPS6416799A (en)	1989-01-20	H-pth (1-34) composition and its preparation
KR910016734A (ko)	1991-11-05	광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도
Bodnaryk	1978	Levels of brain cyclic AMP and cyclic GMP during the initiation of adult development in the bertha armyworm, Mamestra configurata Wlk
EA200200680A1 (ru)	2002-12-26	Применение регулятора роста растений на основе семикарбазона для раннего останавливания роста культурных растений
JPS5495737A (en)	1979-07-28	Stabilized composition containing carpronium chloride